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Quality of life and depressive 
symptoms in Parkinson’s 
disease
Qualidade de vida e sintomas 
depressivos na doença de 
Parkinson
Dear Editor,
Depression is the most common psychiatric comorbidity in 
Parkinson’s disease (PD) and can affect up to 68.1% of patients with 
this movement disorder.1 It is well-known that depression directly 
affects the quality of life and psychosocial functioning of PD patients. 
Thus, we have read with great interest the article by Margis et al. in 
which the authors assessed the influence of depressive symptoms on 
the quality of life of PD patients.2 The authors observed that the 
Geriatric Depression Scale (GDS) score was positively associated 
with the total score in the World Health Organization Quality of Life 
Assessment for older adults and five of its six domains.
To the same end as Margis et al.,2 we have recently used the 39-
item Parkinson’s Disease Questionnaire (PDQ-39) and its eight 
dimensions and the 15-item GDS (GDS-15) to assess quality of 
life and depressive symptoms in PD patients, respectively. We 
divided the patients into two groups (PD without depression and 
PD with depression) according to the GDS-15 cutoff score of eight 
proposed for the screening of depression in PD.3 
The study was approved by the local ethics committee and the 
patients gave their informed consent to participate (HCRP no 
10078/2009).
A total of 114 patients (50.9% male) with a mean age of 64.7 
years (SD = ±12.6) were enrolled. Most participants (n = 92; 
80.7%) had little education (less than 8 years), were not working 
(n = 109; 95.6%), and were married (n = 65; 57%). One limitation 
of this study is the absence of further clinical data. In addition, 
structured clinical interviews (e.g.: SCID-CV) were not applied 
for the diagnosis of depression. This is also a limitation of the 
study by Margis et al.2
The total score in the PDQ-39 and its subscales/dimensions 
strongly correlated with the total score in the GDS-15. The group 
of patients with current depression (GDS-15 ≥ 8) had higher 
scores (p < 0.0001) in the PDQ-39 and its dimensions (Table 
1). Therefore, our findings confirm and expand the results found 
by Margis et al.2
Nowadays, special attention has been given to the non-motor 
symptoms of PD in clinical and research settings. In particular, 
depressive symptoms have been consistently associated with poor 
quality of life, and, in some studies, this correlation is stronger 
than that found for motor symptoms.4
The mobility dimension was strongly correlated with 
depressive symptoms (rho = 0.654) in our study. This is in 
line with the findings of Margis et al.,2 in which depression 
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presented the strongest correlation with the autonomy domain 
(rho = 0.61).2 It is interesting to note that this domain was not 
associated with the Hoehn and Yahr stage or correlated with 
the motor subscale of the UPDRS. This finding suggests that 
depressive symptoms in PD could be more related to autonomy 
than to motor disability. 
This is also consistent with the results of another Brazilian 
study, in which depression was found to be the most consistent 
determinant of quality of life and was an independent predictor 
of quality of life.5
In conclusion, these data highlight the importance of the 
recognition and diagnosis of depression in PD in order to 
implement the appropriate treatment and consequently to improve 
the quality of life of these patients.
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Long-term mood disorder 
antedating the diagnosis of 
Wilson’s disease
Transtorno de humor de 
longa data antecedendo o 
diagnóstico da doença de 
Wilson
Dear Editor,
We evaluated a young patient with a long history of psychiatric 
symptoms and misdiagnosis. After nine years of receiving many 
ineffective symptomatic therapies, she was diagnosed with advanced 
Wilson’s disease (WD). We would like to present this case in order to 
raise awareness around the wide clinical spectrum of WD as well as 
around the need to establishing high clinical suspicion for this diagnosis. 
A 17-year-old woman, the daughter of consanguineous 
parents, was admitted to a university hospital with the diagnosis 
of cryptogenic cirrhosis. Her clinical history revealed that, since 
the age of nine, she had been experiencing a series of episodes of 
excessive fear, anxiety and depression. As her depressive symptoms 
grew steadily worse, she was put on antidepressants, including 
amytriptiline and fluoxetine. At the age of 12, she committed 
two suicide attempts, which were followed by an episode of frank 
mania with psychotic symptoms, evidenced by her attempt to 
bury herself up. Between the ages of 12 and 17, she remained on 
mood stabilizing agents, including carbamazepine and valproic 
acid. This course of treatment was, however, unsuccessful. 
Six months before hospitalization, she experienced weight gain 
and diffuse abdominal pain, followed by nausea and hyporexia. 
Ultrasonography and computed tomography (CT) of the 
abdomen revealed cirrhosis and ascites. Extensive serological 
studies, including HIV, hepatitis B and C, anti-LKM1, anti-
mitochondrial, anti-smooth muscular and anti-nuclear antibodies 
were unrevealing. When admitted to the hospital, her abdominal 
pain had worsened and she presented with severe ascites and 
delirium. Neurological examination showed diffuse hyperreflexia 
and ankle clonus. Kayser-Fleischer rings were present bilaterally. 
Further investigation yielded 13 points on the Child-Pugh’s 
classification (severe ascites, stage II encephalopathy, albumin level 
2.1, international normalized ratio 2.74, bilirubin levels equal to 
4.2). Alpha-fetoprotein at 45.1ng/ml (normal value: < 300ng/
ml) and serum ceruloplasmin at 9.0mg/dl (normal value: 15-
60mg/dl). Cranial CT showed enlargement of the ventricles and 
caudate atrophy. She rapidly became hemodynamically unstable, 
thus making death seemingly inevitable. Upon immediate 
investigation, family members disclosed that her two brothers 
had been diagnosed with WD. Her mother, who used fluoxetine 
on an irregular basis, had been diagnosed with depression and her 
uncle with schizophrenia.
WD is an autosomal recessive genetic disorder related to the 
metabolism of copper, which accumulates in several tissues such 
the brain, liver and cornea. Neurological and psychiatric symptoms 
may occur due to the presence of such copper deposits in the 
brain.1,2 
In nearly 10% of the cases, the first signs of WD may manifest in 
the form of psychiatric symptoms. Several psychiatric manifestations 
have been reported.3 A study with 50 WD patients identified 
excessive talkativeness, aggressive behavior, loss of interest and 
abusiveness as the key behavioral changes.4 Twelve of these patients 
(24%) fulfilled the diagnostic criteria for a psychiatric condition: 
nine patients (18%) were diagnosed with bipolar disorder, two (4%) 
with major depression, and one (2%) with dysthymia. In another 
study,5 11 out of 14 patients with WD had a mood disorder and 
three presented a schizophreniform-illness. 
This case report aims at emphasizing the relevance of 
considering WD as a possible diagnosis in young patients with 
psychiatric symptoms, especially in those with a family and past 
history of jaundice, extrapyramidal features, neuropsychiatric 
disorder and premature deaths of other siblings. Awareness about 
the heterogeneity of WD and a high rate of suspicion may have 
a prognostic implication.
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